Skip to main content

Table 2 Comparison of antithrombotic therapies before and after propensity score matching

From: Thromboembolic and infectious complication risks in TKA and UKA: evidence from a Japanese nationwide cohort

 

Before PS matching

 

After PS matching

 
 

TKA

UKA

χ2 statistics

p-value

TKA

UKA

χ2 statistics

p-value

Edoxaban

141,436 (61.9%)

15,933 (51.9%)

1138

< 0.0001*

19,055 (62.3%)

15,874 (51.9%)

675.1

< 0.0001*

Fondaparinux

4526 (2.0%)

860 (2.8%)

89.4

< 0.0001*

575 (1.9%)

859 (2.8%)

57.6

< 0.0001*

Enoxaparin

22,598 (9.9%)

2469 (8.0%)

106.1

< 0.0001*

3024 (9.9%)

2454 (8.0%)

65.1

< 0.0001*

Aspirin

18,959 (8.3%)

3122 (10.2%)

121.3

< 0.0001*

2316 (7.1%)

3098 (10.1%)

123.9

< 0.0001*

Warfarin

5121 (2.2%)

342 (1.1%)

166.8

< 0.0001*

658 (2.2%)

340 (1.1%)

103.0

< 0.0001*

Clopidogrel

6313 (2.8%)

838 (2.7%)

0.1

0.73

782 (2.6%)

833 (2.7%)

1.7

0.20

Apixaban

5913 (2.6%)

526 (1.7%)

85.6

< 0.0001*

807 (2.6%)

522 (2.2%)

62.5

< 0.0001*

  1. One-to-one PS matching was performed
  2. P-values of < 0.01 are considered significant by the χ2 test; PS propensity score
Back to article page

Knee Surgery & Related Research

ISSN: 2234-2451